Lee Hambright
Stock Analyst at Bernstein
(2.85)
# 2,476
Out of 5,182 analysts
40
Total ratings
46.67%
Success rate
0.07%
Average return
Main Sectors:
Stocks Rated by Lee Hambright
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PODD Insulet | Maintains: Outperform | $380 → $330 | $188.31 | +75.24% | 3 | Feb 19, 2026 | |
| ABT Abbott Laboratories | Maintains: Outperform | $154 → $125 | $92.80 | +34.70% | 7 | Jan 23, 2026 | |
| ISRG Intuitive Surgical | Maintains: Outperform | $740 → $750 | $470.99 | +59.24% | 4 | Jan 23, 2026 | |
| MDLN Medline | Initiates: Outperform | $49 | $45.23 | +8.34% | 1 | Jan 12, 2026 | |
| ZBH Zimmer Biomet Holdings | Maintains: Market Perform | $97 → $99 | $92.59 | +6.92% | 2 | Jan 9, 2026 | |
| TNDM Tandem Diabetes Care | Maintains: Market Perform | $18 → $25 | $19.82 | +26.14% | 2 | Jan 9, 2026 | |
| SYK Stryker | Maintains: Outperform | $450 → $465 | $329.01 | +41.33% | 4 | Jan 9, 2026 | |
| MDT Medtronic | Maintains: Outperform | $111 → $112 | $82.92 | +35.07% | 4 | Jan 9, 2026 | |
| JNJ Johnson & Johnson | Maintains: Market Perform | $193 → $208 | $225.34 | -7.70% | 6 | Jan 9, 2026 | |
| DXCM DexCom | Maintains: Outperform | $84 → $86 | $61.41 | +40.04% | 3 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $92 → $100 | $59.95 | +66.81% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $132 → $135 | $83.46 | +61.75% | 3 | Mar 16, 2022 |
Insulet
Feb 19, 2026
Maintains: Outperform
Price Target: $380 → $330
Current: $188.31
Upside: +75.24%
Abbott Laboratories
Jan 23, 2026
Maintains: Outperform
Price Target: $154 → $125
Current: $92.80
Upside: +34.70%
Intuitive Surgical
Jan 23, 2026
Maintains: Outperform
Price Target: $740 → $750
Current: $470.99
Upside: +59.24%
Medline
Jan 12, 2026
Initiates: Outperform
Price Target: $49
Current: $45.23
Upside: +8.34%
Zimmer Biomet Holdings
Jan 9, 2026
Maintains: Market Perform
Price Target: $97 → $99
Current: $92.59
Upside: +6.92%
Tandem Diabetes Care
Jan 9, 2026
Maintains: Market Perform
Price Target: $18 → $25
Current: $19.82
Upside: +26.14%
Stryker
Jan 9, 2026
Maintains: Outperform
Price Target: $450 → $465
Current: $329.01
Upside: +41.33%
Medtronic
Jan 9, 2026
Maintains: Outperform
Price Target: $111 → $112
Current: $82.92
Upside: +35.07%
Johnson & Johnson
Jan 9, 2026
Maintains: Market Perform
Price Target: $193 → $208
Current: $225.34
Upside: -7.70%
DexCom
Jan 9, 2026
Maintains: Outperform
Price Target: $84 → $86
Current: $61.41
Upside: +40.04%
Oct 24, 2024
Maintains: Outperform
Price Target: $92 → $100
Current: $59.95
Upside: +66.81%
Mar 16, 2022
Upgrades: Outperform
Price Target: $132 → $135
Current: $83.46
Upside: +61.75%